Non-oncology Biopharmaceuticals Market Size Share and Report 2023-2030

Non-oncology Biopharmaceuticals Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Non-oncology Biopharmaceuticals Market is Segmented By Product Type (Biologics, Biosimilars), By Application (Immunology, Endocrinology, Others), By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, &nbsp;2023-2030</h2>

<blockquote>
Non-Oncology Biopharmaceuticals Market&nbsp;size is estimated to reach&nbsp;at a high CAGR of 10.4% during the forecast period (2023-2030).
</blockquote>

Biopharmaceuticals are part of the wider category of therapeutic agents called biologics. Biopharmaceuticals are substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs used to treat various diseases rather than cancer, such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Non-oncology Biopharmaceuticals Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			10.4%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Product Type, By Application, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/non-oncology-biopharmaceuticals-market">Click here</a>

<h3>Non-oncology Biopharmaceuticals Market Dynamics</h3>

The global non-oncology biopharmaceuticals market growth is driven by the&nbsp;increasing launches, approvals, robust pipeline of novel biopharmaceuticals, increasing mergers and collaborations among key players.

Increasing launches, approvals, robust pipeline of novel biopharmaceuticals&nbsp;is expected to drive the growth in the forecast period&nbsp;

Frequent approvals, launches, and a robust pipeline of novel non-oncology biopharmaceuticals for various indications in the market are expected to support the U.S. non-oncology biopharmaceutical&#39;s market growth significantly. For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection to prevent migraine in adults.

In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.

The high price of branded biological products&nbsp;is likely to hinder the market growth

According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.

<h3>COVID-19 Impact Analysis</h3>

With the outbreak of COVID-19, the healthcare sector is adopting new technology that can help hospitals overcome the current pandemic and future medical emergencies. Owing to the growing adoption of new tools and technologies, the global biopharmaceutical fermentation systems market is projected to grow substantially during the coming years. COVID-19 has become a global pandemic and consumed more than a million lives. This has stimulated healthcare companies are developing innovative tools and technologies that can help doctors and medical officers to overcome present and future medical emergencies. For instance, In February 2021, Rentschler Biopharma; a Germany-based contract development and manufacturing organization (CDMO) announced to start commercial manufacture, formulation, and downstream processing of CVnCoV COVID-19 candidate vaccine by CureVac. Similarly, Bayer also announced to manufacture 160 million doses of CVnCoV in 2022. Owing to this, the global biopharmaceutical fermentation systems market is projected to grow exponentially in the coming years.

<h3>Global Non-oncology Biopharmaceuticals Market- Segment Analysis</h3>

The&nbsp;biologics&nbsp;segment&nbsp;is expected to hold the largest share in this market segment

Biologic drugs are used in the treatment of major chronic diseases like autoimmune diseases, which has enabled big pharmaceutical companies, like Eli Lilly and Company, Bristol-Myers Squibb, Novartis, AstraZeneca, and GlaxoSmithKline (GSK), to invest in these products. In 2019, three biological drugs were approved by the United States Food and Drug Administration (FDA), one of which is an anticoagulant solution by Griffons.

There are also increasing investments that have helped in driving the overall market growth. Novartis AG invested around USD 700 million in its biologics facility in Singapore, and Bristol-Myers Squibb invested nearly USD 900 million in an Irish large-scale biologics facility which was expected to be completed by 2019.

Furthermore, biologics prove efficient in treating rheumatoid arthritis and Crohn&rsquo;s disease, which boosts the market even further.

<h3>Non-oncology Biopharmaceuticals Market Geographical Analysis</h3>

North America region holds the largest market share of global non-oncology biopharmaceuticals market 

North American market has dominated the global non-oncology biopharmaceuticals market, and it is estimated to show a similar trend during the forecast period. The primary factors driving the market are the increasing incidences of chronic diseases, well-established pharmaceutical companies, and an increase in biotech companies.

With the rising COVID-19 pandemic, US-based companies are racing to develop vaccines against COVID-19. For instance, in March 2020, a Phase 1 clinical trial began at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle to evaluate an investigational vaccine designed to protect against COVID-19. The vaccine is being developed by NIAID scientists and their collaborators at the biotechnology company Moderna Inc.

For instance, in August 2020, Biocon Biologics India, a fully integrated biosimilars company and a subsidiary of Biocon Ltd, and Mylan NV announced the US launch of Semglee (insulin glargine injection). Hence, all these factors are found to boost the overall market growth in the region.

<h3>Non-oncology Biopharmaceuticals Market Competitive Landscape</h3>

The global non-oncology biopharmaceuticals market is&nbsp;highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include&nbsp;Eli Lilly and Company, GlaxoSmithKline, Novartis, Amgen Inc, AbbVie Inc, AstraZeneca, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd, Elusys Therapeutics and Swedish Orphan Biovitrum. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, Leadiant Biosciences, Inc. got FDA approval for its Revcov (elapegademase-lvlr) injection in the United States in October 2018. Revcovi is a new enzyme replacement therapy (ERT) for pediatric and adult patients with adenosine deaminize severe combination immune deficiency (ADA-SCID).

<h3>Non-oncology Biopharmaceuticals Market &ndash; Key Companies to Watch</h3>

Novartis AG

Overview:&nbsp;Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland established in 1996. It operates business through two divisions: Innovative medicine, Sandoz, made up of two business units &ndash; Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology.

Product Portfolio: It includes product like Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Non-oncology Biopharmaceuticals Market?

Non-oncology Biopharmaceuticals Market is expected to grow at a&nbsp;CAGR of 10.4%&nbsp;during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America&nbsp;region Controls&nbsp;the&nbsp;Non-oncology Biopharmaceuticals Market&nbsp;during 2022-2029

Which is the fastest growing region in the Non-oncology Biopharmaceuticals Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/pet-food-market">Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/organic-pet-food-market">Organic Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/freeze-dried-pet-food-market">Freeze-Dried Pet Food Market</a>

&nbsp;

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; Executive Summary</h3>

	<ol>
		<li>Market Snippet by Product Type</li>
		<li>Market Snippet by Application</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>Increasing launches, approvals, robust pipeline of novel biopharmaceuticals</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>High price of branded biologic products</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>PEST Analysis</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; By Product Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product &amp; Services</li>
			<li>Market Attractiveness Index, By Product &amp; Services</li>
		</ol>
		</li>
		<li>Biologics*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2022-2029</li>
		</ol>
		</li>
		<li>Biosimilars</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Immunology*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2022-2029</li>
		</ol>
		</li>
		<li>Endocrinology</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2022-2029, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By&nbsp;Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By&nbsp;Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By&nbsp;Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By&nbsp;Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By&nbsp;Application</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market- Company Profiles</h3>

	<ol>
		<li>Novartis AG*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Eli Lilly and Company</li>
		<li>GlaxoSmithKline</li>
		<li>Amgen Inc</li>
		<li>AbbVie Inc</li>
		<li>AstraZeneca</li>
		<li>Novo Nordisk A/S</li>
		<li>Takeda Pharmaceutical Company Ltd</li>
		<li>Elusys Therapeutics</li>
		<li>Swedish Orphan Biovitrum&nbsp;(*LIST NOT EXHAUSTIVE*)</li>
	</ol>
	</li>
	<li>
	<h3>Global Non-oncology Biopharmaceuticals Market &ndash; DataM &nbsp;&nbsp;</h3>

	<ol>
		<li>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Non-oncology Biopharmaceuticals Market Value, By Product Type, 2021, 2025 &amp; 2029 ($ Million)

Table 2 Global Non-oncology Biopharmaceuticals Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)

Table 3 Global Non-oncology Biopharmaceuticals Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 4 Global Non-oncology Biopharmaceuticals Market Value, By Product Type, 2021, 2025 &amp; 2029 ($ Million)

Table 5 Global Non-oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 6 Global Non-oncology Biopharmaceuticals Market Value, By Application, 2021, 2025 &amp; 2029 ($ Million)

Table 7 Global Non-oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 8 Global Non-oncology Biopharmaceuticals Market Value, By Region, 2021, 2025 &amp; 2029 ($ Million)

Table 9 Global Non-oncology Biopharmaceuticals Market Value, By Region, 2019-2029 ($ Million)

Table 10 North America Non-Oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 11 North America Non-Oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 12 North America Non-Oncology Biopharmaceuticals Market Value, By Country, 2019-2029 ($ Million)

Table 13 South America Non-Oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 14 South America Non-Oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 15 South America Non-Oncology Biopharmaceuticals Market Value, By Country, 2019-2029 ($ Million)

Table 16 Europe Non-oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 17 Europe Non-oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 18 Europe Non-oncology Biopharmaceuticals Market Value, By Country, 2019-2029 ($ Million)

Table 19 Asia-Pacific Non-oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 20 Asia-Pacific Non-oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 21 Asia-Pacific Non-oncology Biopharmaceuticals Market Value, By Country, 2019-2029 ($ Million)

Table 22 Middle East &amp; Africa Non-oncology Biopharmaceuticals Market Value, By Product Type, 2019-2029 ($ Million)

Table 23 Middle East &amp; Africa Non-oncology Biopharmaceuticals Market Value, By Application, 2019-2029 ($ Million)

Table 24 Eli Lilly and Company: Overview

Table 25 Eli Lilly and Company: Product Portfolio

Table 26 Eli Lilly and Company: Key Developments

Table 27 GlaxoSmithKline: Overview

Table 28 GlaxoSmithKline: Product Portfolio

Table 29 GlaxoSmithKline: Key Developments

Table 30 Amgen Inc: Overview

Table 31 Amgen Inc: Product Portfolio

Table 32 Amgen Inc: Key Developments

Table 33 AbbVie Inc: Overview

Table 34 AbbVie Inc: Product Portfolio

Table 35 AbbVie Inc: Key Developments

Table 36 AstraZeneca: Overview

Table 37 AstraZeneca: Product Portfolio

Table 38 AstraZeneca: Key Developments

Table 39 Novo Nordisk A/S: Overview

Table 40 Novo Nordisk A/S: Product Portfolio

Table 41 Novo Nordisk A/S: Key Developments

Table 42 Takeda Pharmaceutical Company Ltd: Overview

Table 43 Takeda Pharmaceutical Company Ltd: Product Portfolio

Table 44 Takeda Pharmaceutical Company Ltd: Key Developments

Table 45 Eleusis Therapeutics: Overview

Table 46 Eleusis Therapeutics: Product Portfolio

Table 47 Eleusis Therapeutics: Key Developments

Table 48 Swedish Orphan Biovitrum: Overview

Table 49 Swedish Orphan Biovitrum: Product Portfolio

Table 50 Swedish Orphan Biovitrum: Key Developments

Table 51 Novartis AG: Overview

Table 52 Novartis AG: Product Portfolio

Table 53 Novartis AG: Key Developments

List of Figures

Figure 1 Global Non-oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 2 Global Non-oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 3 Global Non-oncology Biopharmaceuticals Market Share, By Region, 2021 &amp; 2029 (%)

Figure 4 Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 5 Global Non-oncology Biopharmaceuticals Market Y-o-Y Growth, By Product Type, 2021-2029 (%)

Figure 6 Biologics: Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 7 Biosimilars: Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 8 Global Non-oncology Biopharmaceuticals Market Y-o-Y Growth, By Application, 2021-2029 (%)

Figure 9 Immunology: Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 10 Endocrinology: Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 11 Others: Global Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 12 Global Non-oncology Biopharmaceuticals Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 13 North America Non-Oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 14 North America Non-Oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 15 North America Non-Oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 16 North America Non-Oncology Biopharmaceuticals Market Share, By Country, 2021 &amp; 2029 (%)

Figure 17 South America Non-Oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 18 South America Non-Oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 19 South America Non-Oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 20 South America Non-Oncology Biopharmaceuticals Market Share, By Country, 2021 &amp; 2029 (%)

Figure 21 Europe Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 22 Europe Non-oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 23 Europe Non-oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 24 Europe Non-oncology Biopharmaceuticals Market Share, By Country, 2021 &amp; 2029 (%)

Figure 25 Asia-Pacific Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 26 Asia-Pacific Non-oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 27 Asia-Pacific Non-oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 28 Asia-Pacific Non-oncology Biopharmaceuticals Market Share, By Country, 2021 &amp; 2029 (%)

Figure 29 Middle East &amp; Africa Non-oncology Biopharmaceuticals Market Value, 2019-2029 ($ Million)

Figure 30 Middle East &amp; Africa Non-oncology Biopharmaceuticals Market Share, By Product Type, 2021 &amp; 2029 (%)

Figure 31 Middle East &amp; Africa Non-oncology Biopharmaceuticals Market Share, By Application, 2021 &amp; 2029 (%)

Figure 32 Eli Lilly and Company: Financials

Figure 33 GlaxoSmithKline: Financials

Figure 34 Amgen Inc: Financials

Figure 35 AbbVie Inc: Financials

Figure 36 AstraZeneca: Financials

Figure 37 Novo Nordisk A/S: Financials

Figure 38 Takeda Pharmaceutical Company Ltd: Financials

Figure 39 Elusys Therapeutics: Financials

Figure 40 Swedish Orphan Biovitrum: Financials

Figure 41 Novartis AG: Financials